Mission Statement, Vision, & Core Values of Regulus Therapeutics Inc. (RGLS)

In the complex world of biopharmaceuticals, a clear mission, a compelling vision, and strong core values are essential for success. Have you ever wondered what drives Regulus Therapeutics Inc. (RGLS), a company focused on discovering and developing innovative medicines targeting microRNAs? With approximately $75.8 million in cash, cash equivalents, and short-term investments as of December 31, 2024, and research and development expenses of $35.4 million for the year ended December 31, 2024, how does this company stay focused on its goals?

Understanding the guiding principles behind Regulus Therapeutics can provide valuable insights into their strategic direction and long-term objectives. What are the core beliefs that shape their decisions and how do these values translate into their daily operations? Read on to discover the mission statement, vision, and core values that define Regulus Therapeutics and drive their commitment to delivering life-changing therapeutics, particularly for orphan kidney diseases.

Regulus Therapeutics Inc. (RGLS) An Overview of

Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on discovering and developing drugs targeting microRNAs (miRNAs). These are small molecules that play a crucial role in regulating gene expression. The company aims to create new therapeutic options for patients with a variety of diseases. As of April 2025, Regulus continues its research and development efforts, striving to advance its pipeline of miRNA-targeting drugs through clinical trials.

Regulus Therapeutics' strategy revolves around modulating microRNAs to treat diseases with unmet medical needs. Their work involves identifying specific microRNAs that are implicated in disease pathways and then designing drugs that can either inhibit or enhance the activity of these microRNAs. This approach allows for highly targeted therapies with the potential for greater efficacy and fewer side effects compared to traditional treatments. The company's pipeline includes programs focused on kidney diseases, cancer, and other therapeutic areas.

Regulus Therapeutics Inc. recently reported its financial results, reflecting the company's progress and financial standing. For the year ended December 31, 2024, Regulus reported a net loss of $29.1 million, or $2.59 per share. As of December 31, 2024, Regulus had cash and cash equivalents totaling $26.5 million. These figures reflect the company's ongoing investment in research and development activities aimed at advancing its pipeline of miRNA-targeting therapeutics.

Regulus Therapeutics is dedicated to advancing the field of microRNA therapeutics. Interested in learning more about why Regulus Therapeutics is making waves in the biopharmaceutical industry? Find out more here: Exploring Regulus Therapeutics Inc. (RGLS) Investor Profile: Who’s Buying and Why?

Regulus Therapeutics Inc. (RGLS) Mission Statement

Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. The company's mission is centered on delivering life-changing therapeutics to patients with orphan kidney diseases. They are particularly focused on improving the lives of patients and their families affected by these conditions.

Regulus leverages its expertise in oligonucleotide drug discovery and development to build a pipeline of microRNA-based therapeutics. Their approach involves targeting the underlying biology of diseases with novel and potentially powerful methods. The company's pipeline programs target kidney diseases with high unmet needs, including Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Regulus Therapeutics is dedicated to scientific rigor, creative problem-solving, and collaboration across various departments and disciplines. The company is inspired by individuals worldwide affected by genetic kidney diseases and other genetically-based, orphan diseases.

Regulus maintains its corporate headquarters in San Diego, CA. As of April 11, 2025, Regulus Therapeutics's stock price is $1.78, with a market cap of $118 million and 66.2 million shares outstanding.

Regulus reported its fourth quarter and year-end 2024 financial results on March 13, 2025. The company's financial data for the year 2024 includes:

• Enterprise Value (EV): $16.662 million
• EBITDA: ($49.693 million)
• Net Income: ($46.358 million)
• Total Assets: $84.181 million
• Total Debt: $274,000

Regulus Therapeutics is actively involved in clinical trials, with a focus on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of its drug candidates. On March 27, 2025, Regulus announced the successful completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the treatment of ADPKD.

The company values its employees and offers competitive compensation and benefits packages, including health, vision, and dental insurance, life insurance, flexible spending accounts, a 401K plan, vacation, and stock options.

To gain more insights into the company's investors and their motivations, check out this resource: Exploring Regulus Therapeutics Inc. (RGLS) Investor Profile: Who’s Buying and Why?

Regulus Therapeutics Inc. (RGLS) Vision Statement of

Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs (miRNAs). These are small ribonucleic acid molecules that regulate gene expression. Understanding the company's vision, mission, and core values provides insight into its strategic objectives and operational principles. For a broader understanding of the company, you might find this resource helpful: Regulus Therapeutics Inc. (RGLS): History, Ownership, Mission, How It Works & Makes Money

Mission Statement

While a current, explicit mission statement for Regulus Therapeutics Inc. as of April 2025 is not readily available, we can infer their mission from their activities and focus. Regulus Therapeutics' mission can be understood as:

• To advance the understanding of microRNA biology and leverage this knowledge to develop novel therapeutics.
• To create innovative treatments for diseases with significant unmet medical needs by modulating microRNA activity.
• To build a pipeline of microRNA-targeted drug candidates, focusing on areas such as kidney disease and oncology.

Vision

As of April 2025, the specific vision statement for Regulus Therapeutics Inc. is not explicitly declared. However, based on their strategic direction and focus areas, a deduced vision might be:

To be a leader in the field of microRNA therapeutics, transforming the treatment landscape for patients with debilitating diseases through innovative and targeted medicines.

This vision encompasses several key aspects:

• Leadership in microRNA Therapeutics: Aiming to be at the forefront of research and development in this novel therapeutic area.
• Transforming Treatment Landscape: Focusing on creating therapies that significantly improve patient outcomes and address unmet medical needs.
• Innovative and Targeted Medicines: Developing drugs that precisely modulate microRNA activity to treat the underlying causes of disease.

Core Values

Similar to the mission and vision statements, Regulus Therapeutics' core values are not explicitly listed in readily available sources as of April 2025. Nevertheless, we can infer these values from their operational focus, scientific rigor, and engagement in the biopharmaceutical industry:

• Innovation: A commitment to pioneering research and development of novel therapeutic approaches.
• Scientific Excellence: Upholding high standards of scientific rigor and integrity in their research activities.
• Patient-Centricity: Focusing on the needs of patients and developing therapies that improve their lives.
• Collaboration: Fostering partnerships and collaborations to advance their research and development efforts.
• Integrity: Adhering to ethical principles and maintaining transparency in their operations.

These inferred core values likely guide the company's culture, decision-making, and interactions with stakeholders.

Regulus Therapeutics Inc. (RGLS) Core Values of

Regulus Therapeutics Inc. operates with a set of guiding principles that shape its corporate culture, business strategies, and interactions with stakeholders. While specific details of their core values can evolve, they generally reflect a commitment to innovation, patient well-being, and ethical conduct. Understanding these values provides insight into how Regulus Therapeutics approaches its mission and goals.

Here's a look at some potential core values and how they might manifest within the company:

Innovation

Innovation is likely a central value for Regulus Therapeutics, given its focus on developing novel microRNA therapeutics. This commitment to innovation could be demonstrated through:

• R&D Investment: Allocating a significant portion of its resources to research and development activities. For example, in the fiscal year 2024, Regulus Therapeutics reported R&D expenses of $22.4 million, reflecting its dedication to advancing its pipeline of microRNA therapeutics.
• Strategic Partnerships: Collaborating with other companies and academic institutions to access new technologies and expertise.
• Scientific Publications: Encouraging its scientists to publish their research findings in peer-reviewed journals to share knowledge and advance the field.

Patient Focus

A strong patient focus is crucial for any biotechnology company. Regulus Therapeutics might demonstrate this value through:

• Clinical Trial Design: Designing clinical trials with patient needs and preferences in mind.
• Patient Advocacy: Engaging with patient advocacy groups to understand their needs and perspectives.
• Compassionate Use Programs: Providing access to its investigational therapies for patients with serious unmet medical needs, when possible and appropriate.

Integrity

Operating with the highest ethical standards is essential for building trust with patients, investors, and other stakeholders. Regulus Therapeutics could emphasize integrity through:

• Compliance Programs: Implementing robust compliance programs to ensure adherence to all applicable laws and regulations.
• Transparency: Communicating openly and honestly about its research, clinical trials, and business practices.
• Ethical Decision-Making: Fostering a culture of ethical decision-making at all levels of the organization.

Collaboration

Collaboration can be a key value, especially in the complex and rapidly evolving field of biotechnology. Regulus Therapeutics might foster collaboration through:

• Cross-Functional Teams: Creating cross-functional teams to bring together diverse perspectives and expertise.
• Open Communication: Encouraging open communication and knowledge sharing among employees.
• External Partnerships: Building strong relationships with external partners, such as researchers, clinicians, and suppliers.

Commitment to Excellence

Striving for excellence in all aspects of its operations is likely a core value for Regulus Therapeutics. This could be reflected in:

• Quality Control: Implementing rigorous quality control measures to ensure the safety and efficacy of its products.
• Continuous Improvement: Continuously seeking ways to improve its processes and performance.
• Employee Development: Investing in employee training and development to build a highly skilled and motivated workforce.

For more insights into Regulus Therapeutics Inc.'s financial standing, see Breaking Down Regulus Therapeutics Inc. (RGLS) Financial Health: Key Insights for Investors.